- Home
- DBVT vs PAVS Comparison
DBVT vs PAVS Comparison
Compare DBVT & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- PAVS
- Stock Information
- Founded
- DBVT 2002
- PAVS 2004
- Country
- DBVT France
- PAVS United States
- Employees
- DBVT N/A
- PAVS N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- DBVT Health Care
- PAVS Health Care
- Exchange
- DBVT Nasdaq
- PAVS Nasdaq
- Market Cap
- DBVT 102.0M
- PAVS 90.2M
- IPO Year
- DBVT N/A
- PAVS 2019
- Fundamental
- Price
- DBVT $6.46
- PAVS $1.35
- Analyst Decision
- DBVT Strong Buy
- PAVS
- Analyst Count
- DBVT 2
- PAVS 0
- Target Price
- DBVT $22.50
- PAVS N/A
- AVG Volume (30 Days)
- DBVT 1.1M
- PAVS 7.8K
- Earning Date
- DBVT 05-06-2025
- PAVS 01-01-0001
- Dividend Yield
- DBVT N/A
- PAVS N/A
- EPS Growth
- DBVT N/A
- PAVS N/A
- EPS
- DBVT N/A
- PAVS N/A
- Revenue
- DBVT $4,200,000.00
- PAVS $6,544,819.00
- Revenue This Year
- DBVT $1,679.52
- PAVS N/A
- Revenue Next Year
- DBVT $535.67
- PAVS N/A
- P/E Ratio
- DBVT N/A
- PAVS N/A
- Revenue Growth
- DBVT N/A
- PAVS N/A
- 52 Week Low
- DBVT $0.44
- PAVS $0.32
- 52 Week High
- DBVT $7.28
- PAVS $1.85
- Technical
- Relative Strength Index (RSI)
- DBVT 65.77
- PAVS 45.04
- Support Level
- DBVT $3.91
- PAVS $1.33
- Resistance Level
- DBVT $7.28
- PAVS $1.40
- Average True Range (ATR)
- DBVT 0.60
- PAVS 0.03
- MACD
- DBVT 0.20
- PAVS -0.01
- Stochastic Oscillator
- DBVT 75.67
- PAVS 28.57
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.